cyrilzakka/clinical-trials huggingface dataset:
Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org

The purpose is to collect data for ALS research. The data will be used to learn more about the origin of ALS and to improve quality of care for people with ALS. The information you provide in the ALS registry will be used to evaluate variations in patient care, adherence to standards of care and also to help foster ALS research.

Any person who has been diagnosed with ALS by a physician can enroll into this registry.

The information you provide in the ALS registry will be used to evaluate variations in patient care, adherence to standards of care and also to help foster ALS research. An additional focus of this website will be to educate participating patients and visitors to this site about ongoing ALS research.

Eligibility Criteria:
Inclusion Criteria:

* There are no inclusion and exclusion criteria beyond the fact that a person needs to have ALS in order to enroll.
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well gemcitabine and cisplatin work in treating patients with metastatic kidney cancer.

OBJECTIVES:

* Assess the response rate of patients with metastatic renal cell carcinoma treated with gemcitabine and cisplatin.
* Assess toxicity of this regimen in these patients.

OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 4 months.

PROJECTED ACCRUAL: Approximately 29-38 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically proven metastatic renal cell carcinoma
* No brain metastases

PATIENT CHARACTERISTICS:

Age:

* Over 18

Performance status:

* ECOG 0-2

Life expectancy:

* At least 12 weeks

Hematopoietic:

* WBC at least 3,500/mm\^3
* Hematocrit at least 30%
* Platelet count at least 100,000/mm\^3

Hepatic:

* Bilirubin no greater than 2.0 mg/dL
* AST and ALT no greater than 1.5 times upper limit of normal

Renal:

* Creatinine no greater than 1.5 mg/dL OR
* Creatinine clearance at least 60 mL/min

Cardiovascular:

* No uncontrolled hypertension
* No myocardial infarction within the past 8 weeks

Other:

* Not pregnant or nursing
* Fertile patients must use effective contraception
* No other prior malignancy within the past 5 years except nonmelanomatous skin cancer, carcinoma in situ of cervix, prostate intraepithelial neoplasia, or superficial bladder cancer
* No significant psychiatric disease
* No active infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No more than 2 prior biologic response modifier regimens
* No concurrent biologic therapy

Chemotherapy:

* No prior chemotherapy
* No other concurrent chemotherapy

Endocrine therapy:

* Not specified

Radiotherapy:

* Prior radiotherapy allowed if measurable disease is outside radiation port
* At least 28 days since prior radiotherapy
* No concurrent radiotherapy

Surgery:

* Prior surgery allowed
TMS for Suicidal Crisis in Active Duty SMs

The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects than current treatments such as Electroconvulsive Therapy (ECT) and medication therapies. There will be 6 months of follow-up, in order to establish the ongoing and lasting therapeutic effect of TMS.

The programmatic-level objective of the study is to address the goals of the Army STARRS Program and the Suicide Prevention for America's Veterans Act through implementation of an effective acute treatment for patients psychiatrically admitted in suicidal crisis as well as other patients at high-risk for suicide. This is achieved by application of TMS, which provides a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects and less incapacitation than current treatments such as ECT and pharmacologic therapies. A recent study led by the senior consultant of this proposal demonstrated tolerance and efficacy for a new, high-dose regimen of TMS in a VA population with an average age of 47. The objective of the proposed study is to extend the application of TMS to a younger population of Active Duty Service Members (SM) in order to demonstrate efficacy for returning veterans of the Middle East wars, in particular, as well as the civilian young adult population. TMS dosage in the proposed study is recalibrated to commercially-standard levels in order to provide consistency with devices currently in clinical operation. In addition, follow-up in the proposed study continues for 6 months in order to establish persistence and durability of the therapeutic effect of TMS.

Eligibility Criteria:
Inclusion Criteria:

* All Active Duty SMs (regardless of sex, ethnicity, sexual or religious orientation) who are admitted to Eisenhower Army Medical Center (EAMC) Inpatient Psychiatric Service (IPS) with active suicidality or elevated risk for suicide regardless of most psychiatric diagnostic co-morbidity (see exclusion criteria). This includes in-patient admissions for suicidality and outpatient SMs with a Columbia-Suicide Severity Rating Scale (C-SSRS) score ≥3.
* Age 18 to 60
* Able to speak and read English.

Exclusion Criteria:

* Combative with staff.
* Comatose/catatonia.
* Incapacity owing to active mania or psychosis.
* Epilepsy, multiple sclerosis, or cerebrovascular accident.
* Non-removable metal in the head (Shrapnel; plates, aneurysm coils/clips; metal tattoos etc.)
* Implantable devices (pacemakers, stimulators, etc.)
* Schizophrenic or borderline personality.
* Positive screen for pregnancy.
* Already receiving TMS as a treatment for depression.
* Non-English reading and speaking subjects
Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

There are several types of cameras allowing its performance:

* Conventional Anger cameras and,
* CZT (Cadmium-Zinc-Telluride) semiconductor cameras. At the Nancy University Hospital, the nuclear medicine department has a wide-field Cadmium-Zinc-Telluride camera: VERITON-CT (Spectrum Dynamics). The interpretation of this examination is purely visual.

The objectives are therefore to:

* Create the first international database of semi-quantitative values in 3D scintigraphy with Datscan performed with a VERITON-CT camera.
* Compare this database with another database from a conventional Anger camera (Lyon Nuclear Medicine Department) to show its superiority.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease.
* The clinical diagnosis can only be established after two years of clinical follow-up.

Exclusion Criteria:

* Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes,
* patients who died before two years of clinical follow-up,
* patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.